Study of IL-2 receptor expression after chemoimmunotherapy in patients treated for metastatic malignant melanoma. 1994

R Mouawad, and M Ichen, and O Rixe, and A Benhammouda, and E Vuillemin, and M Weil, and D Khayat, and C Soubrane
Department of Medical Oncology, Salpetrière Hospital, Paris, France.

Using flow cytometry, cellular IL-2 receptors were studied before and following chemoimmunotherapy combination in 20 patients with metastatic malignant melanoma (MMM). Patients received cisplatin (100 mg/m2) at days 1 and 28, recombinant IL-2 by continuous infusion from days 3 to 6, 17 to 21, 31 to 34, and 45 to 49. Interferon-alpha (IFN-alpha) was given subcutaneously three times weekly. In terms of clinical response, we observed 55% objective response (complete: 15%). When pretreatment blood samples were compared with those of healthy donors, we did not observe any change in low (alpha chain) and high affinity receptor (alpha + beta) expression. In contrast, intermediate affinity p75 (beta chain) expression was decreased significantly (P < or = 0.0001) in MMM patients. During treatment, we found a dramatic increase of beta chain as well as high affinity (alpha + beta) expression in responding patients, as soon as IL-2 therapy began. Furthermore, the increase of beta chain expression was limited to natural killer (NK) cells (CD56+). In non-responding patients, on the other hand, increase of both receptors was seen only at day 31. These data suggest the involvement of beta chain expression in the mechanism of cell activation after chemoimmunotherapy. Moreover, this early beta chain expression is correlated with the clinical response to chemoimmunotherapy.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D008297 Male Males
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D005260 Female Females

Related Publications

R Mouawad, and M Ichen, and O Rixe, and A Benhammouda, and E Vuillemin, and M Weil, and D Khayat, and C Soubrane
January 2007, The Cochrane database of systematic reviews,
R Mouawad, and M Ichen, and O Rixe, and A Benhammouda, and E Vuillemin, and M Weil, and D Khayat, and C Soubrane
February 2018, The Cochrane database of systematic reviews,
R Mouawad, and M Ichen, and O Rixe, and A Benhammouda, and E Vuillemin, and M Weil, and D Khayat, and C Soubrane
August 1997, European journal of cancer (Oxford, England : 1990),
R Mouawad, and M Ichen, and O Rixe, and A Benhammouda, and E Vuillemin, and M Weil, and D Khayat, and C Soubrane
January 2010, Journal of immunotherapy (Hagerstown, Md. : 1997),
R Mouawad, and M Ichen, and O Rixe, and A Benhammouda, and E Vuillemin, and M Weil, and D Khayat, and C Soubrane
April 1987, American journal of clinical oncology,
R Mouawad, and M Ichen, and O Rixe, and A Benhammouda, and E Vuillemin, and M Weil, and D Khayat, and C Soubrane
October 1991, Seminars in oncology,
R Mouawad, and M Ichen, and O Rixe, and A Benhammouda, and E Vuillemin, and M Weil, and D Khayat, and C Soubrane
May 2000, Gan to kagaku ryoho. Cancer & chemotherapy,
R Mouawad, and M Ichen, and O Rixe, and A Benhammouda, and E Vuillemin, and M Weil, and D Khayat, and C Soubrane
January 1993, European journal of cancer (Oxford, England : 1990),
R Mouawad, and M Ichen, and O Rixe, and A Benhammouda, and E Vuillemin, and M Weil, and D Khayat, and C Soubrane
January 1995, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
R Mouawad, and M Ichen, and O Rixe, and A Benhammouda, and E Vuillemin, and M Weil, and D Khayat, and C Soubrane
July 1978, Cancer treatment reports,
Copied contents to your clipboard!